Market Research Assistance

On the Web
Refine Result

By Date

Last Month
Last 3 Months
Last 6 Months
Last Year
Last 2 Years

By Price

< $1000
$1000-$2500
$2501-$4000
$4001-$5500
$5501-$7500
$7501-$9000
>$9000
Hepatitis Drugs

    Hepatitis Drugs Market Research Reports

    Titlepublishedprice

    Hepatitis C – Pipeline Review, H1 2014

    By Global Markets Direct
    "......rative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involv......"
    28-Feb-2014$2500

    Fendrix (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$3495

    PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – Global Drug Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$9995

    Heplisav (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$3495

    PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – US Drug Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$4995

    Hexyon (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$3495

    PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – 5EU Drug Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$6995

    Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$3495

    PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – Japan Drug Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$4995

    Pediarix (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022

    By GlobalData
    "...... liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. ......"
    31-Jan-2014$3495
    Live Chat
    Live Chat by Comm100